Current Clinical Trials | ECHO Associates

A Beacon of Light on Your Cancer Care Journey


Current Trials

Genetic Risk Assessment

ECHO Open to Accrual Clinical Trials

Updated: 09/08/22

Bladder / Urothelial

A Phase II Open-Label study of IMMU-132 in Metastatic Urothelial Cancer after failure of Platinum-Based regimen or Anti-PD-1/PD-L1 based Immunotherapy

SGN22E-002 / EV-103
A Study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

SGN22E-003 / EV-302
An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.


A Phase III, randomized, Open-Label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, HER2-Negative, locally advanced or Metastatic Breast Cancer



A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating, Multi-Center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 in Combination with Leucovorin/5-Fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer patients

A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

Gritstone / GO-010
A Phase 2/3, randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer

MRT 849-010 / Krystal-10
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy


JZP 712-402
Emerge 402: Phase IV Observational Study to Collect Safety and Outcome data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive

Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

D910MC00001 MERMAID-2
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy

A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein

First Line Metastatic

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab  compared with Durvalumab in Patients with Locally-Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not progressed after Concurrent Platinum-Based Chemoradiation

GSK 213400
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as maintenance Therapy in participants whose disease has remained stable or responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer (Zeal-1L)

Mirati 849-007
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Second Line Metastatic

GSK 213410 ***Enrollment on hold***
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (Costar Lung)


D8227C00001 / ACE-LY-312 / Escalade
A phase 3, Randomized, Double-Blind, Placebo-controlled study of Acalabrutinib in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects 65 years or younger with previously untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Prostate Cancer

64091742PCR0002 / TIME / Prevalence
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer

AMPLITUDE / 67652000PCR3002
A Phase 3 Randomized, Placebo-controlled, Double-Blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone for the treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC).

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment

Solid Tumors

JZP712-201 / Emerge-201
A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants with Advanced or Metastatic Solid Tumors

PBI-200-101/TIME-Tempus Trial
A Phase 1-2 Study of PBI200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors


Lung Screening

International Early Lung Cancer Action Program: Enrollment and Screening Protocol

Supportive Care

Bespoke (Natera)
BESPOKE Study of ctDNA Guided Immunotherapy

ESR 22-21698 (EIMPRIS)
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients

FRNM-008 (Freenome)
A Case Control Study for the Development of Multiomics Blood Test for Cancer Screeening

Ready 1 / CUSA-081-HEM-01 /YYA36723
Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)

Seer – 020102 (SeerPro)
A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers

THR-CS-001 / THRIVE / DETECT-ASCEND 2  ***Prostate & Breast Cohort Closed***
Exact Sciences Thrive LLC / Detecting Cancers Earlier Through Elective Plasma-Based CancerSEEK Testing – Ascertaining Serial Cancer Patients to Enable New Diagnostic II (DETECT-ASCEND 2)

To learn about our newest study on biomarker testing, click here.

To learn about our newest study on bladder cancer, click here.

For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research or 860-886-8362.